Krcmery vladimir
Antibiotic resistance in
antibiotic free environment
Antibiotic resistance in the absence of
An association between antibiotic use and the development of clinical
resisitance has been clearly documented in several cases
Use of macrolides and resistance in S. pyogenes Use of penicillins and resistance S. pneumoniae Use of floroquinolones and resistance in Enterobacteriacea and P. aeruginosa Use of third-generation cephalosporins and resistance in Enterobacteriacea Use of carbapenems and resistance in P. aeruginosa Use of linezolid and resistance in E. faecium
Reversal of antibiotic resisitance following antibiotic-restriction
policies has been documented in some cases
Decrease of macrolide resistance in S. pyogenes after restriction in Finland Decrease of penicillins resisitance in S. pneumoniae after restriction in
Hungary, Iceland, France
Pallecchi et al. Anti. Infect. Ther. 6(5):725-732 (2008)
Antibiotic resistance in the absence
of antimicrobial use
High rates of acquired antibiotic resistance have been
detected among commensal bacteria isolated from humans and wild animals not subjected to significant antibiotic exposure and living in remote areas of the planet
This observations underscore the mechanisms involved
in the emergence and spread of antibiotic resistance
Better understanding of this mechanisms is crucial to
improve strategies for antibioti-resistance control
Evidence for acquired under conditions of low
or minimal antibiotic exposure
The only available bacterial collection predating the antibiotic era is
the Murray collection, including clinical isolates of Enterobacteriacae from widely separated areas
collected during during 1917-1954
In these isolates the presence of acquired resistance traits was
found to be negligible
This observation strongly emphasized the role of antibiotic use in
promoting dissemination of acquired resistance among pathogenic bacteria
Hughes and Datta, Nature 302:725-726 (1983)
Studies on antibiotic resistance in commensal
bacteria from humans living in remote settings
The first studies was conducted in the 1960s in an
isolated community of Kalahari bushmen in South Africa, which was free of drugs and had been in contact with other humans for a period of approximately 10 years
In that community fecal carriage of enteric bacteria with
acquired resistance traits was found to be low overall, and was limited to ampicillin resistance in E. coli
Mare IJ, Nature 220:1046-1047 (1968)
Summary of studies on acquired resistance in
commensal enteric bacteria from remote human
populations with low or minimal antibiotic exposure
Approximate
Hughes et al.
Mare et al.
Wakson et al.
Grenet et al.
Bartoloni et al.
Sladeckova et al.
Nepalese village with very low
access to allopathic medicines
Investigation on the fecal carriege of
antibiotic-resistant lactose-fermenting enterobacteria from healthy individuals
Resistance: amoxicillin, tetracycline,
trimethoprim-sulfamethoxazole, chloramphenicol, much lower quinolones
Walson et al. J.Infect. Dis. 184:1163-1169 (2001)
Three traditional communities of Wayampis Amerindians, where exchanges with the exterior were limited and antibiotic consumption was moderate overall
Resistance pattern similar to that found in Nepal
Three individuals from this community were found to carry commensal E.coli resistant to expanded-spectrum cephalosporins due producing of the TEM-52 extended spectrum ß –lactamase (ESBL)
Resistant bacteria could be introduced into the community from antibiotic-exposed settings (e.g., through villagers that had been previously hospitalized)
Grenet et al. Emerg. Infect. Dis. 10:1150-1153 (2004)
Bolivian Chaco region
To date, most remote human communities investigated for carriage of antibiotic-resistant bacteria are two Amerindian communities located in the Bolivian Chaco region and the Peruvian Alto Amazonas district
High rates of fecal carriage of E.coli resistant to tetracycline, ampicillin, trimethoprim-sulfamethoxazole and chloramphenicol were detected in both communities
No resistance was observed for quinolones
Molecular characterization of resistant isolates from this area revealed a considerable variety of acquired resistance genes, entirely alike those encountered in resistant isolates from antibiotic-exposed settings in the same geographical areas
Bartoloni et al. J. Infect. Dis. 189:1291-1294 (2004)
We tested 182 HIV
negative patients from Mapuordit in South Sudan
105 isolates – most frequently were
Enterobacteriaceae, S. aureus, Moraxella catharralis, H. influezae,S. pyogenes
All 105 isolates were 100% sensitive
to all antibiotics
Sladeckova et al. Journal of infection, 53 (4):291-292 (2005)
We carried Cambodian children
before of treatment with HAART
High colonization with MR-GNB
(e.g. ceftazidime-resistant) Enterobacter spp. and Klebsiella pneumoniae in children who were antibiotic and HAART-naive
Colonization GPB - S. pyogenes
Shahum, Krcmery et al. Journal of Antimicrobial Chemotherpy, 60 (1):194-197
Reason for spread of MDR bacteria
from SE Asia
Not developing countries, any
move , many height level hospitals
Overproduction of generic
Exposition fake antibiotics with
less antibiotic (low doses promote resistance)
Huge concentrated poplulation
(Indonesia, India, China) on a squere of SE Asia – 10 % OF WS
Diarrheic regions whit
Emergence of a new antibiotic resistance mechanism
in India, Pakistan, and the UK: a molecular,
biological, and epidemiological study
Identification of 44 isolates with NDM-1 in Chennai, 26 in Haryana,
37 in the UK, and 73 in other sites in India and Pakistan
NDM-1 was mostly found among Escherichia coli (36) and Klebsiella
pneumoniae (111), which were highly resistant to all antibiotics except to tigecycline and colistin
Most isolates carried the NDM-1 gene on plasmids: those from UK
and Chennai were readily transferable whereas those from Haryanawere not conjugative. Many of the UK NDM-1 positive patients had traveled to India or Pakistan within the past year, or had links with these countries.
Kumarasamy et al. The Lancet Infectious Diseases,10 (9):597 – 602 (2010)
Carbapenem resistance in E. coli from Australia due to metallo-beta-lactamase
NDM-1
Emergence of MBL NDM-1 in Australia after its recent identification in India and
UK, in an E. coli isolate accumulating emerging broad-spectrum resistance determinants, including the ESBL CTX-M-15 and two 16S RNA methylases
Poirel et al., ICAAC, 2010
Dissemination of NDM-1-producing Enterobacteriaceae in India
A new metallo-ß-lactamase, NDM-1 was identified in a K. pneumoniae (KPN) from
a Swedish patient of Indian origin
SENTRY program (2006-2007) – occurence and characterization of NDM-1-
producing strains from India
15 (1%; 6 E. coli, 6 KPN and 3 E. cloaceae) isolates from New Delhi (2 sites),
Mumbai and Pune carried blaNDM-1
All isolates were resistant to penicillins, cephalosporins and aminoglycosides, and
susceptibility only to tigecycline and polymyxin B (two isolates were resistant)
Deshpande et al. , ICAAC, 2010
Recognition of NDM-1 AMONG Enterobacteriaceae in the United states
This is the first report of bla NDM in the United states and of metallo-beta –
lactamase carriage among Enterobacteriacae in the US
These isolates are resistant to nearly all available therapeutic agents
Limbago et al., ICAAC, 2010
Antimicrobial resistance and Extended-spectrum ß-lactamase
(ESBL)-producing clinical isolates from urinary tract infections in Rwanda, East-Africa
The findings of the present study reveal a significant icrase of resistance
to various groups of antimicrobial drugs and prevalence of ESBL producers is first described among UTI pathogens
Muvunyi, ICAAC, 2010
Emergence of metallo-ß-lactamase NDM-1 PRODUCING Klebsiella
pneumoniae in Kenya
Emergence of MBL NDM-1 in Africa, after the recent identification of
NDM-1 producers in India and UK
Worringly the K. pneumoniae isolates studied here accumulated many
threatening mechanisms of resistance to antibiotics
Poirel et al., ICAAC, 2010
The characteristic of mettallo-ß-lactamase producing E. coli isolates
in Canada from a patient with recent travel to India
This is the firs report of E.coli ST101 with NDM-1 metalo-
carbapenemase and Ctx-M15 ESBL from Canada
Peirano, ICAAC, 2010
Carbapenem-resistant Klebsiella pneumoniae (CRKP) in post-acute
care facilities (PACF) IN Israel: A national intervention
There is a major burden of CRKP carriage in PACF
Ben-David et al., ICAAC, 2010
Multidrug-resistant Enterobacteriaceae including NDM-1 metallo-ß-
lactamase producers are predominant paththogens of HCAIs in an
Indian teaching hospital
Carbapenems were in little use but selection pressure exerted by other classes
was sufficient to select carbapenemsmase due to co-selection suggesting role of single plasmid carrying multiple resistnace genes
Sarma Male et al., ICAAC, 2010
How to reduce the spread of resistance?
How to reduce the spread of resistance ?
Hospital antibiotic policy
How to reduce the spread of resistance ?
Internal cooperation and meetings
How to reduce the spread of resistance?
Improving health care infrastructure
Burundi Celebrity ATB-R free Environment
In Sub-Sahara Africa and Latin
America ATB-R in remote settings is minimal
In South and SE Asia multiresistant strains are emergence and they spread all over the world from e.g. Taiwan, Hong Kong, India (e.g. PVDM-1, PRP, ERY-R S. pyogenes)
Selective pressure generated by the use of antibiotics in clinical, veterinary, husbandry and agricultural practices is considered the major factor responsible for the emergence and spread of antibiotic-resistant bacteria since the beginning of the antibiotic era
Acquired resistance traits can also be found in bacteria isolates from humans not subjected to significant antibiotic exposure and living in remote areas of the planet
Thanks for your attention!
Source: http://www.krankenhaus-hygiene.at/images/vortrag_krcmery.pdf
F-MELT series, Issue2, February 2011 Formulating Taste Masked and High Quality ODT of Poorly Water Soluble Drugs In this paper, we present case studies with taste masking technology and application of wet granulation technologies to develop ODTs of Loratadine, a water insoluble drug, and Famotidine, a slightly water
Philips SMART Biphasic therapy Application note Philips SMART Biphasic therapy Since Philips introduced the first biphasic waveform for an external defibrillator in 1996, biphasic therapy has gained acceptance and is now recognized as the standard of care. However, the various defibrillator manufacturers recommend a wide range of energy (joules) dosages. This is because defibrillator manufacturers have created distinct biphasic waveform "formulations." So each manufacturer recommends energy doses appropriate for their shock formulation. While energy (joules) remains entrenched in defibrillator vocabulary as a descriptor of shock strength, current (amperes) has been shown to be a better predictor. For meaningful shock strength comparisons of biphasic waveforms, it's necessary to look beyond energy levels and compare the current delivered to the patient.